Zai Lab nabs speedy Chi­na reg­u­la­to­ry re­view for PARP drug Ze­ju­la

Chi­nese reg­u­la­to­ry of­fi­cials are sig­nal­ing that they’re ready to whisk Ze­ju­la through the reg­u­la­to­ry process.

Zai Lab $ZLAB said this morn­ing that the Cen­ter for Drug Eval­u­a­tion of Chi­na’s Na­tion­al Med­ical Prod­ucts Ad­min­is­tra­tion has of­fered a pri­or­i­ty re­view for this drug, the PARP ther­a­py ni­ra­parib in-li­censed from Tesaro. They’re look­ing for an OK in Chi­na to mar­ket the drug for ovar­i­an can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER